184 related articles for article (PubMed ID: 25865683)
1. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Barni S
Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):124-31. PubMed ID: 25865683
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Jin SF; Fan ZK; Pan L; Jin LM
Hepatobiliary Pancreat Dis Int; 2017 Jun; 16(3):236-244. PubMed ID: 28603091
[TBL] [Abstract][Full Text] [Related]
3. Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis.
Kasuga A; Hamamoto Y; Takeuchi A; Okano N; Togasaki K; Aoki Y; Suzuki T; Kawasaki K; Hirata K; Sukawa Y; Kanai T; Takaishi H
Invest New Drugs; 2018 Oct; 36(5):939-948. PubMed ID: 29572783
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
[TBL] [Abstract][Full Text] [Related]
5. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
6. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
7. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Vogel A; Ciardiello F; Hubner RA; Blanc JF; Carrato A; Yang Y; Patel DA; Ektare V; de Jong FA; Gill S
Cancer Treat Rev; 2016 Nov; 50():142-147. PubMed ID: 27676174
[TBL] [Abstract][Full Text] [Related]
8. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
10. Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.
Makris EA; MacBarb R; Harvey DJ; Poultsides GA
Ann Surg Oncol; 2017 Aug; 24(8):2371-2378. PubMed ID: 28397190
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer.
Colloca G; Venturino A; Guarneri D
Clin Colorectal Cancer; 2016 Sep; 15(3):264-76. PubMed ID: 26776098
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.
Bria E; Milella M; Gelibter A; Cuppone F; Pino MS; Ruggeri EM; Carlini P; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2007 Aug; 110(3):525-33. PubMed ID: 17577216
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis.
Tian W; Ding W; Kim S; Xu X; Pan M; Chen S
Pancreatology; 2013; 13(4):415-22. PubMed ID: 23890141
[TBL] [Abstract][Full Text] [Related]
14. Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy.
Kasuga A; Hamamoto Y; Takeuchi A; Kawasaki K; Suzuki T; Hirata K; Sukawa Y; Takaishi H; Kanai T
Cancer Chemother Pharmacol; 2017 Mar; 79(3):595-602. PubMed ID: 28236000
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
16. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
Petrelli F; Barni S
Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
[TBL] [Abstract][Full Text] [Related]
17. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Hecht JR; Lonardi S; Bendell J; Sim HW; Macarulla T; Lopez CD; Van Cutsem E; Muñoz Martin AJ; Park JO; Greil R; Wang H; Hozak RR; Gueorguieva I; Lin Y; Rao S; Ryoo BY
J Clin Oncol; 2021 Apr; 39(10):1108-1118. PubMed ID: 33555926
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
[TBL] [Abstract][Full Text] [Related]
20. Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.
Moriwaki T; Yamamoto Y; Gosho M; Kobayashi M; Sugaya A; Yamada T; Endo S; Hyodo I
Br J Cancer; 2016 Apr; 114(8):881-8. PubMed ID: 27031848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
